Susanne Geistlich
Villigen, AG, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: June 17, 2025
First-in-human administration of [161Tb]Tb-SibuDAB and comparative dosimetry with standard [177Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study.
Journal: European journal of nuclear medicine and molecular imaging
Published: October 16, 2024
In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study.
Journal: EJNMMI research
Published: January 17, 2024
First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum.
Journal: European journal of nuclear medicine and molecular imaging
Published: December 21, 2023
161Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of 161Tb into the Clinic.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: November 29, 2022
Antibody-guided Molecular Imaging of Aspergillus Lung Infections in Leukemia Patients.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 18, 2021
Neuroimaging with Radiopharmaceuticals Targeting the Glutamatergic System.
Journal: Chimia
Published: December 28, 2020
A Step-by-Step Guide for the Novel Radiometal Production for Medical Applications: Case Studies with 68Ga, 44Sc, 177Lu and 161Tb.
Journal: Molecules (Basel, Switzerland)
Published: January 30, 2020
Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: July 10, 2019
Radiation dosimetry of [18F]-PSS232-a PET radioligand for imaging mGlu5 receptors in humans.
Journal: EJNMMI research
Published: November 13, 2018
Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog 177Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: January 04, 2018
Last Updated: 09/26/2026